Advising at the intersection of policy and market access, delivering patient-first solutions
Aery
Policy & Access
Partners
Aery Policy & Access Partners is a trusted advisor to the biopharmaceutical industry on navigating today’s most pressing drug pricing and reimbursement challenges. Leading with a 360 degree view of healthcare stakeholders, our work is bespoke, combining salient insights on present-day policy, multi-stakeholder perspectives and business acumen, we help our clients have a clear path forward for navigating a complex landscape so that their research and development may lead to breakthrough innovations for patients.
Specialties
MFN, IRA and MFP Strategy
340B Policy and Manufacturer Strategy
Understanding U.S. Government Payers at the Federal and State Levels
Policy Strategy Related to Drug Pricing or Market Access Concerns
Business Mitigation Solutions
Intersection of Global Drug Pricing and U.S. Evolving Policies
Client Team Training
Federal Agency and Hill Education
Upcoming Speaking Highlights
-
September 30 - October 2, 2026
learn more > -
October 5 - 7, 2026
Insights from Leading Trade Associations and CMS
learn more > -
October 19 - 21, 2026
Executive Panel
learn more > -
December 2, 2026
Outlook for 2027: What Current Drug Pricing Trends Mean for Gross-to-Net Performance
learn more > -
December 7 - 8, 2026
Beyond the Buzzwords: Understanding the Real Impact of 340B Duplicate Discounts
learn more > -
September 14 - 15, 2027